ReviewCureus2026
Emerging Role of Immunotherapy in Neoadjuvant, Adjuvant, and Perioperative Management of Gastric Cancer.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains a major global cause of cancer mortality despite improvements in surgery, perioperative chemotherapy, radiotherapy, and supportive care. For resectable locally advanced gastric and gastroesophageal junction adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) has become a major standard of care; however, recurrence remains frequent, reflecting the persistence of micrometastatic disease and biological resistance. Immune checkpoint inhibitors have transformed the management of advanced gastric cancer and are now being investigated in curative-intent settings. The rationale for earlier use is strong: intact tumor antigen, preserved lymphatic priming, and potential eradication of micrometastases may enhance immune-mediated control. This review discusses the emerging role of immunotherapy in neoadjuvant, adjuvant, and perioperative gastric cancer management, with a particular focus on pivotal trials including DANTE, Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab (NEONIPIGA), KEYNOTE-585, ATTRACTION-5, CheckMate-577, and MATTERHORN. MATTERHORN represents the most important recent phase III advance, showing that perioperative durvalumab plus FLOT significantly improves event-free survival compared with FLOT alone in resectable gastric or gastroesophageal junction adenocarcinoma. Future integration of immunotherapy will require careful biomarker selection, interpretation of survival endpoints, toxicity management, and adaptation to regional treatment standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.